Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05534477 · ClinicalTrials.gov registry record
Verily Clinical Study Watch Analytical Validation Study
A clinical trial of Chronic Disease and Healthy Population, sponsored by Verily Life Sciences.
- Active
- Registry status
- 100
- Enrollment target
- 1
- Study location
NCT05534477: Active study of Chronic Disease and Healthy Population, sponsored by Verily Life Sciences.
NCT05534477 is a study of Chronic Disease and Healthy Population that is active but no longer recruiting, run by Verily Life Sciences. The registered enrollment target is 100 participants, below the 89,941-participant average among 48 other Chronic Disease trials with a reported enrollment target (100% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05534477, a study of Chronic Disease and Healthy Population, is active but no longer recruiting, sponsored by Verily Life Sciences.
- ACTIVE NOT RECRUITING
- Registry status
- 100 participants
- Enrollment target
- 1
- Study location
Study Summary
This study is designed to evaluate the performance of the Verily Clinical Study Watch for the quantification of participants' movement and pulse rate when the wearer is at rest.
Primary Outcome
To evaluate the accuracy of the Verily Clinical Study Watch's ability to measure pulse rate when wearer is at rest during unsupervised free-living conditions. Pulse rate measurements will be compared against heart rate output from the reference device (FDA cleared ECG patch).
Conditions Studied
Interventions
- DEVICE Verily Clinical Study Watch
- DEVICE Vivalink ECG Patch
- DEVICE Modus StepWatch 4
Study Locations (1)
California
- Verily Life Sciences - South San Francisco
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 100 participants |
| Start Date | 2023-09-18 |
| Est. Completion | 2025-06 |
What the registry record for NCT05534477 still lists
NCT05534477 is an observational study that tracks outcomes without assigning an intervention. The registered 100 participants enrollment target is mid-sized for trials with a published cap, below the 89,941-participant average among 48 other Chronic Disease trials with a reported enrollment target (100% lower).
The record links to 2 conditions, with Chronic Disease appearing as the primary indexed condition, and to 3 interventions - of which Verily Clinical Study Watch is the first listed.
NCT05534477 reports a single indexed study location in California.
Frequently Asked Questions
What is clinical trial NCT05534477 about?
NCT05534477 is a clinical study titled "Verily Clinical Study Watch Analytical Validation Study". This study is designed to evaluate the performance of the Verily Clinical Study Watch for the quantification of participants' movement and pulse rate when the wearer is at rest.
What is the current status of trial NCT05534477?
This trial is currently active not recruiting. The enrollment target is 100 participants. The study started on 2023-09-18. Estimated completion is 2025-06.
What conditions does trial NCT05534477 study?
This clinical trial studies the following conditions: Chronic Disease, Healthy Population.
What interventions are being tested in trial NCT05534477?
The interventions under investigation include: Verily Clinical Study Watch (DEVICE), Vivalink ECG Patch (DEVICE), Modus StepWatch 4 (DEVICE).
Who is sponsoring clinical trial NCT05534477?
This trial is sponsored by Verily Life Sciences, which has 10 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05534477 being conducted?
This trial has 1 study location across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Chronic Disease
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT05534477's enrollment target sits among peer trials
100 32nd of 48 higher than 16 of 48 other Chronic Disease trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Chronic Disease trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Click & Pick Study
RECRUITING · NA
-
Evaluation of AI Cost Prediction Model to Enroll Patients in Complex Care Management Program
RECRUITING · NA
-
RIVER At Home Ketamine Protocols
RECRUITING
-
Effects of Personalized Exercise Prescriptions Through Mobile Health on Physical Activity and Health Outcomes in the Cancer Survivors
RECRUITING · NA
-
Comparative Effectiveness of IIMR Versus CDSMP
RECRUITING · NA
-
Training Community Members to be Coaches to Deliver the HealthyLifetime Program
RECRUITING · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01048281 · 100 participants
Clinical & Pathological Studies of Upper Gastrointestinal Carcinoma
- NCT01161199 · 100 participants
The Use of Leukapheresis to Support HIV Pathogenesis Studies
- NCT01327690 · 100 participants · Early Phase 1
Mental Health in Veterans and Families After Group Therapies
- NCT01730781 · 100 participants
Imaging Cannabinoid Receptors Using Positron Emission Tomography (PET) Scanning
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI